Kang 1
The health care industry is fiercely competitive and the company has suffered long-term losses. The competition in health care industry is becoming more and more fierce. Faced with the impact of the rational consumption concept of public health care products and the booming e-commerce network sales model, the company's health care products business lacks competitiveness because of the aging products and excessive dependence on traditional sales. Income growth is weak.
Stripping the health care products business is conducive to integrating resources and focusing on the main pharmaceutical industry. The company will transfer the health care products company, which will be integrated into its framework system by Kang Group. At the same time, listed companies can further concentrate resources to strengthen and expand the main pharmaceutical industry, which is generally beneficial to the interests of all shareholders of listed companies.
Main products: Qianliekang Pulean tablets/capsules, Tianbaoning Ginkgo biloba leaves/capsules, Jin Aokang, Changyanning, Alexin, Niuhuang Shangqing capsules, Zhenshiming series, Kedaling tablets, Bitan, Tangbeike, Xiatianwu series, Keting tablets, amikacin sulfate, spectinomycin hydrochloride and Ginkgo biloba extract.
2. Tomson Bianjian
Tomson Bianjian fully integrates domestic and foreign authoritative nutrition and health research institutions and other resources, focusing on innovative research and development of "new functions, new raw materials and new technologies".
A comprehensive and scientific dietary supplement system has been established, including protein, vitamins, minerals and other functional dietary supplements. In addition to providing high-quality nutrition, Tomson Bianjian pays more attention to solving people's health problems and improving the quality of life.